Abstract | OBJECTIVE: The best antithymocyte globulin (ATG) preparation for induction suppression in kidney transplant recipients is still not clear. The aim of this study was to identify short- and long-term outcomes in kidney transplant recipients who received thymoglobulin or ATGAM as an induction agent. METHODS: We retrospectively reviewed patients who underwent kidney transplantation from 1996 to 2010. Recipients were classified according to the ATG preparation. RESULTS: CONCLUSION:
|
Authors | J M Kim, H R Jang, J S W Ko, C H D Kwon, M S Kwak, W S Hur, S J Kim, G S Kim, J-W Joh, S-K Lee, H Y Oh |
Journal | Transplantation proceedings
(Transplant Proc)
Vol. 44
Issue 1
Pg. 171-4
(Jan 2012)
ISSN: 1873-2623 [Electronic] United States |
PMID | 22310607
(Publication Type: Comparative Study, Journal Article)
|
Copyright | Copyright © 2012. Published by Elsevier Inc. |
Chemical References |
- Antilymphocyte Serum
- Biomarkers
- Immunosuppressive Agents
- Creatinine
- thymoglobulin
|
Topics |
- Adult
- Antilymphocyte Serum
(adverse effects, therapeutic use)
- Bacterial Infections
(etiology)
- Biomarkers
(blood)
- Creatinine
(blood)
- Delayed Graft Function
(blood, etiology, prevention & control)
- Female
- Graft Rejection
(blood, immunology, prevention & control)
- Graft Survival
(drug effects)
- Humans
- Immunosuppressive Agents
(administration & dosage, adverse effects)
- Kaplan-Meier Estimate
- Kidney Transplantation
(adverse effects, immunology)
- Male
- Middle Aged
- Proportional Hazards Models
- Republic of Korea
- Retrospective Studies
- Risk Assessment
- Risk Factors
- Time Factors
- Treatment Outcome
- Young Adult
|